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Synthesis and reactivity of cytotoxic platinum(II) complexes of 
bidentate oximes: a step towards the functionalization of 
bioactive complexes. 
Daniela Belli Dell’ Amico,[a] Marialuigia Colalillo,[a] Lisa Dalla Via,[b] Martina Dell’ Acqua,[a] Aída N. 
García-Argáez,[b] Mariafrancesca Hyeraci,[b] Luca Labella, [a] Fabio Marchetti[a] and Simona 
Samaritani*[a] 
 
Abstract: Two new complexes of platinum(II) bearing 
triphenylphosphine and bidentate oxime ligands [Pt(Cl)(PPh3){(κ
2
-
N,O)-[1(C(R)=N(OH)-2(O)C10H6]}] (R = H, Me) were synthesized in 
good yields starting from trans-[PtCl(μ-Cl)(PPh3)]2. The structure of 
[Pt(Cl)(PPh3){(κ
2
-N,O)-[1(CH=N(OH)-2(O)C10H6]}] was determined 
by single crystal X-ray diffraction. Both complexes showed good 
antiproliferative properties in vitro against HeLa, A2780 and 
A2780cis cancer cell lines. They react cleanly with alkylating agents 
in the presence of aqueous bases under phase transfer catalysis 
conditions, affording the corresponding O-alkylation products 
[Pt(Cl)(PPh3){(κ
2
-N,O)-[1(HC=N(OR')-2(O)C10H6]}] (R' = CH2CH2Cl, 
CH2Ph, (CH2)4Br) in good yields.  
Introduction 
After the discover and the approval of cisplatin [1] as powerful 
anticancer agent, every year hundreds of new platinum 
complexes are prepared and tested, in the continuous and 
challenging search for less toxic and more specific drugs. In this 
context, non-conventional analogues of cisplatin able to 
circumvent resistance and new synthetic approaches addressed 
to drug delivery are important research topics.[2] In this view, the 
presence of reactive functional groups can be of great help. 
Among unconventional platinum derivatives, those containing 
phosphane ligands [3] have often shown an interesting ability to 
circumvent cisplatin resistance, with mechanisms significantly 
different from cisplatin mode of action [3d,g,j,l] and with the 
phosphane ligand playing a crucial role in the intracellular drug 
uptake.[3k,l] In this context, we have recently been interested in 
oxime derivatives.[3a] In fact, the known acidity of oxime hydroxyl 
residue, which is greatly enhanced upon coordination to 
metals,[4] can be exploited both for the formation of non-bonding 
interactions and for synthetic modifications of the complexes. It 
is known, indeed, that some platinum oxime complexes possess 
interesting antiproliferative properties.[5] In our previous study [3a] 
concerning monodentate [PtCl2(PPh3)(oxime)] derivatives, we 
had observed an interesting reactivity of these systems with 
aqueous bases under phase transfer catalysis conditions, 
leading to the formation of rare dinuclear oximate complexes.[3a] 
Nevertheless, the scarce water solubility of the prepared 
compounds and their instability in DMSO had prevented us from 
testing them in vitro as antiproliferative agents. In this work, we 
report the synthesis and the in vitro antiproliferative properties of 
two stable, PPh3, oxime Pt(II) chelated complexes and we show 
that the oxime hydroxyl group can be conveniently exploited to 
functionalize the compounds. 
Results and Discussion 
Synthesis of the complexes 
Bidentate oxime ligands 1-2 (Figure 1) used in this work were 
prepared starting from the corresponding 2-
hydroxyarylcarbonylic compounds, according to reported 
procedures.[6] 
 2 1  
Figure 1. Bidentate 2-hydroxyarylald- and ketoximes used in this work 
Platinum complexes were prepared in refluxing 1,2-DCE 
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solution, starting from trans-[PtCl(μ-Cl)(PPh3)]2 
[7] and following 
the reaction by 31P-NMR. As expected, the bridge-splitting 
reaction is initially guided by the strong trans effect exerted by 
the PPh3 group, leading to the formation of a monodentate trans-
(Z) kinetic intermediate (Scheme 1). At variance with the 
analogous monodentate systems we studied earlier,[3a] the 
formation of the kinetic intermediate was not followed by any 
isomerization in solution. A slow elimination of HCl was instead 
observed, leading to single chelation products 3-4, which were 
recovered by the usual work-up procedures and characterized 
by IR (ATR), 1H-, 31P-, 13C- and 195Pt-NMR (Figures SI1-SI8). 
Since the elimination of gaseous HCl (Scheme 1) took up to two 
weeks, with maximum isolated yields ranging from 30 to 47 %, 
the syntheses were repeated in the presence of silver acetate. 
R = Me (3); H (4)
2 oxime
2
- HCl(g)
3-4
 
Scheme 1. Synthesis of chelated complexes 3 and 4 
In fact, while silver ion could facilitate the intermediate 
dehalogenation, the presence of acetate ion could help the 
deprotonation of phenolic residue on the oxime ligand. In these 
conditions the reactions were much faster (2h) and the isolated 
yield of the bidentate complexes could be improved (70-89%).  
It is worth to note that deprotonation of the phenolic function was 
selective and the desired chelated complex was the only product 
observed. No deprotonation of oxime groups by silver acetate 
was observed in our system at variance with previous reports.[8] 
Complexes 3-4 are soluble in common chlorinated solvents and 
scarcely soluble in water or ethanol. They are soluble in DMSO 
and their stability was checked by 31P NMR in a 20 mM DMSO 
solution containing H2O (5 vol.-%). It is known, in fact, that, in 
some cases, the presence of water can favor the reactivity of 
platinum substrates toward DMSO.[ 9 ] In these conditions the 
solutions were stable up to 24h at r.t. (Figures SI9-SI10).Stock 
solutions of the complexes for the in vitro assays were thus 
prepared in DMSO and stocked at -18 °C. 
For complex 4 the structure was confirmed by single crystal X-
ray diffraction.  
The structure of complex 4 is represented in Figure 2, while the 
most significant bond lengths and angles are reported in Table 1. 
Coordination around platinum center is square planar, with small 
deviations from ideal bond angles. The oxime chelates the metal 
through nitrogen atom and the deprotonated phenolic group on 
position 2 of the aromatic moiety. The platinum coordination 
sphere is completed by a PPh3, in trans to the oxime nitrogen 
atom, and by a chloride ion. Pt-O and Pt-N bond lengths can be 
compared with those in the complex [Pt(o-OC6H4CH=NOH)2]
[10]. 
Pt-O bond distance in 4 (1.981(3) Å) is quite close to the one 
reported by Pombeiro et al. (1.978(5) Å), while Pt-N bond in 4 
(2.032(3) Å) is, as expected, slightly longer (2.063(4) Å vs. 
1.974(6) Å), due to the presence of the phosphine ligand in trans 
position. 
 
 
Figure 2. Molecular structure of complex 4 
Table 1. Bond lengths [Å] and angles [°] for complex 4. 
Bond lengths [Å] Bond angles [°] 
Pt(1)-O(2) 1.981(3) O(2)-Pt(1)-N(1) 89.23(11) 
Pt(1)-N(1) 2.032(3) O(2)-Pt(1)-P(1) 89.23(7) 
Pt(1)-P(1) 2.2488(9) N(1)-Pt(1)-P(1) 178.45(8) 
Pt(1)-Cl(1) 2.3086(10) O(2)-Pt(1)-Cl(1) 179.60(9) 
N(1)-C(1) 1.290(5) N(1)-Pt(1)-Cl(1) 90.68(8) 
N(1)-O(1) 1.393(4) P(1)-Pt(1)-Cl(1) 90.86(4) 
  C(1)-N(1)-O(1) 112.1(3) 
  C(1)-N(1)-Pt(1) 127.6(2) 
  O(1)-N(1)-Pt(1) 120.3(2) 
 
Reactivity 
In our previous study [3a] concerning platinum complexes of 
monodentate oximes we found that aqueous bases, under 
phase transfer reaction conditions, deprotonate oxime hydroxyl 
group, affording rare dinuclear derivatives, where two oximate 
ligands bridge two platinum centres in a “head to tail” 
coordination mode (Scheme 2). 
2
DCE/NaOHaq
TBAClcat
 
Scheme 2. Reactivity of complexes of monodentate oxime with aqueous 
bases 
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Complex 4 was tested for its reactivity in the same conditions. In 
a typical experiment, 4 was dissolved in 1,2-dichloroethane and 
the resulting solution was treated with an aqueous NaOH, in the 
presence of 5% of tetrabutyl ammonium chloride. The reaction 
progress was checked by 31P-NMR on samples taken from the 
organic phase at different time spans. The spectroscopic 
analyses showed the gradual disappearing of the signal of 4 
(6.38ppm, 1JP-Pt = 3821 Hz), in favor of a new one at 6.01ppm 
(1JP-Pt = 3807 Hz). The conversion was complete in 24 h at 25 °C 
and a new, single product (5) was recovered from the organic 
phase after the usual work-up procedures. This complex was 
characterized spectroscopically. Unexpectedly, collected data 
showed that no dinuclear derivative had formed, but O-alkylation 
by the solvent had occurred (Scheme 3). 
4 5
DCE/NaOH
aq
TBACl
cat
 
Scheme 3. O-alkylation of complex 4 by 1,2-DCE 
Alkylation of the oxime hydroxyl residue was evident in the 1H-
NMR spectrum of isolated (53%) 5, where oxime OH singlet at 
10.53 ppm was absent and two triplet signals were observed at 
4.70 and 3.82 ppm, both accounting for two hydrogen atoms and 
attributable to OCH2 and CH2Cl residues respectively. This 
interpretation is in agreement with the chemical shift and the 
coupling constant observed in the 31P-NMR spectrum of 5, which 
are both similar to those observed for the precursor. Finally, in 
the IR (ATR) spectrum, the broad absorption due to OH 
stretching in 4 had disappeared. The preparation of 5 is 
interesting, because 2-chloroethyl residues are typical of strong 
DNA alkylating agents and recently some Pt(II) and Pt(IV) 
complexes containing an analogous fragment were found active 
against pancreatic cancer cell lines.[11] 
Interestingly, the observed reactivity was extended to alkylating 
agents other than 1,2-DCE. For instance, 4 was alkylated with 
benzyl bromide and with 1,4-dibromobutane under the same 
conditions, replacing 1,2-DCE with chloroform (Scheme 4).  
R = Bz (6); (CH
2
)
4
Br (7)4
RBr (CHCl
3
)/NaOH
aq
TBACl
cat
 
Scheme 4. O-alkylation of complex 4 by RBr 
In these cases, the reactions were much faster, being complete 
in 2-7 h and only a slight excess of alkylating agent was 
necessary. Complexes 6 and 7 were recovered in good yields. 
In all the cases studied, the O-alkylation process was 
chemoselective and no products arising from substitution at the 
metal centre were observed.  
 
In vitro assays 
Complexes 3 and 4 were tested in vitro for their antiproliferative 
activity against three human tumor cell lines, HeLa (cervix 
adenocarcinoma), A2780 (ovarian carcinoma) and A2780cis 
(ovarian carcinoma cisplatin resistant). Data, expressed as GI50 
(μM), are reported in Table 2. 
  
Table 2. Cell growth inhibition values in the presence of examined complexes 
and cisplatin as reference.  
Complex 
Cell Line GI50
a
 (μM) 
HeLa
 
A2780
 
A2780cis
  
3 3.53±0.99 0.62±0.12 2.73±0.21 
4 3.67±0.30 0.94±0.28 1.40±0.06 
cisplatin 1.42±0.32 0.80±0.06 7.01±0.26 
[a] Values are the mean ± SD of at least three independent experiments  
 
Complexes 3 and 4 are able to exert a significant 
antiproliferative activity on both HeLa and A2780 cell lines. In 
particular, on HeLa cells the cytotoxicity induced by the new 
complexes appear quite lower with respect to that observed for 
cisplatin, while on A2780 cells comparable GI50 values were 
obtained. Notably, notwithstanding the similar effect on A2780 
cells, sensitive toward cisplatin, on the corresponding resistant 
cell line, A2780cis, the cytotoxic capacity of 3 and 4 is 
significantly higher with respect to that of the drug, suggesting 
the possibility for these new Pt(II)-based structures to overcome 
the resistance phenomenon. In this connection, 4 shows the 
most interesting behavior with a GI50 value on A2780cis 
comparable to that obtained on A2780 cells. These results point 
to the new platinum(II) complexes bearing triphenylphosphine 
and bidentate oxime ligand as a lead moiety worth to be further 
developed for the synthesis of more efficacious Pt(II) complexes. 
Conclusions 
Two new platinum(II) complexes bearing PPh3 and bidentate 
oxime ligands were prepared in good yields from trans-[PtCl(μ-
Cl)(PPh3)]2 in the presence of silver acetate. Both complexes 
showed antiproliferative properties when tested against HeLa, 
A2780 and A2780cis cancer cell lines. In particular, they were 
able to circumvent resistance towards A2780cis cells, with 4 
showing the best results. The mechanism of action is currently 
under investigation. The synthesized complexes reacted cleanly 
with alkylating agents in the presence of bases under PTC 
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conditions, affording only the O-alkylation products. The reaction 
appears to be general, allowing the functionalization of the 
complex without affecting the coordination sphere of the 
bioactive platinum centre. This reactivity could be exploited to 
link the platinum center to fragments capable to bind to 
particular receptors, bioactive moieties or suitable nanoparticles, 
thus opening the way toward cooperation effects and drug 
delivery. 
Experimental Section 
Materials and general methods 
 All manipulations were performed under a dinitrogen atmosphere, 
if not otherwise stated. Solvents and liquid reagents were dried according 
to reported procedures[12]. 1H-, 13C-, 31P- and 195Pt NMR spectra were 
recorded with a Bruker ‘‘Avance DRX400’’ spectrometer, in CDCl3 
solution if not otherwise stated. Chemical shifts were measured in ppm 
(δ) from TMS by residual solvent peaks for 1H and 13C, from aqueous 
(D2O) H3PO4 (85 %) for 
31P and from aqueous (D2O) hexachloroplatinic 
acid for 195Pt. A sealed capillary containing C6D6 was introduced in the 
NMR tube to lock the spectrometer to the deuterium signal when non-
deuterated solvents were used. FTIR spectra in solid phase were 
recorded with a Perkin–Elmer ‘‘Spectrum One’’ spectrometer, equipped 
with an ATR accessory. Elemental analyses (C, H, N) were performed at 
Dipartimento di Scienze e Tecnologie Chimiche, Università di Udine and 
at Dipartimento di Chimica e Chimica Industriale, Università di Pisa. 
Trans-[Pt(µ-Cl)Cl(PPh3)]2 
[7] was prepared according to a reported 
procedure. Aldoxime ligands 1-2 (Figure 1) were prepared by a slight 
modification of a described procedure.[6] Hydroxylamine hydrochloride 
(NH2OH·HCl) (99 %, Carlo Erba) and silver acetate (98 %, Sigma 
Aldrich) were used without further purification. 
In the text, the following abbreviations were used: 1,2-dichloroethane 
(1,2-DCE), tetrabutylammonium chloride (TBACl). 
General procedure for the synthesis of bidentate oxime complexes  
A Schlenk tube equipped with a magnetic stirrer was charged with [Pt(µ-
Cl)Cl(PPh3)]2 (0.300-0.500 g), the suitable bidentate oxime (oxime/Pt = 
1.03 molar ratio), silver acetate (Ag(OAc)/oxime = 1.00 molar ratio) and 
1,2-DCE. The mixture was shielded from light and stirred at 25 °C. A 
yellow solution was obtained and a colorless solid formed almost 
immediately. The suspension was stirred until the maximum conversion 
was reached (31P-NMR, 2 h), then was filtered on a short package of 
celite. The liquid phase was concentrated under vacuum up to one third 
of the original volume and then treated with heptane. The yellow solid 
precipitated was filtered, washed with heptane and dried under vacuum. 
For each of the bidentate complexes, the oxime used, the % isolated 
yield and the characterization are reported. 
 [Pt(Cl)(PPh3){(κ
2-N,O)-[1(O)-2(C(Me)N(OH)C10H6]}] (3) 
Oxime 1; 70 %. C30H25ClNO2PPt∙1.5H2O Anal. Calc.: C 50.0, H 3.9, N 
1.9%. Exp.: C 50.0, H 4.0, N 1.7 %. IR (ATR, 𝜈, cm-1): 3257; 3053; 2960; 
1625; 1593; 1570; 1544; 1501; 1481; 1456; 1435; 1418; 1398; 1372; 
1338; 1260; 1245; 1188; 1133; 1099; 1021; 998; 975; 900; 868; 796; 
747; 710. 1H NMR: 10.81 (s, 1H, OH); 7.87-7.82 (m, 6H, Harom PPh3); 
7.76-7.71 (m, 2H, Harom); 7.54-7.44 (m, 9H, Harom PPh3), 7.35-7.31 (m, 1H, 
Harom); 7.08 (d, 1H, J=8.7 Hz, Harom); 6.82-6.79 (m, 1H, Harom); 6.59 (d, 1H, 
J=8.7 Hz, Harom); 2.60 (s, 3H, CH3). 
13C NMR: 158.3; 134.8 (d, J=10.7 
Hz); 131.1; 128.5 (d, J=11.2 Hz); 128.4; 128.3; 128.2; 127.7; 127.5 125.9 
(d, J=74.4 Hz); 125.5; 124.3; 116.9; 116.4; 77.2; 15.06. 31P NMR: 6.73 
(JP-Pt=3891Hz). 
195Pt NMR:-2938 (JP-Pt=3891 Hz). 
[Pt(Cl)(PPh3){(κ
2-N,O)-[1(CHN(OH)-2(O)C10H6]}] (4) 
Oxime 2; 89%. C29H23ClNO2PPt∙H2O. Anal. Calc.: C 50.0, H 3.6, N 
2.0 %; Exp.: C 49.8, H 3.2, N 2.1 %. IR (ATR, 𝜈, cm-1): 3237; 3055; 2963; 
2903; 2860; 1628; 1599; 1548; 1515; 1482; 1455; 1435; 1424; 1405; 
1354; 1332; 1298; 1260; 1189; 1092; 1017; 947; 865; 797; 745; 707; 692. 
1H NMR: 10.53 (s, 1H, OH); 9.21 (d, 1H, J=9.6 Hz, CHN); 7.92 (d, 1H, 
J=9.0 Hz, Harom); 7.84-7.79 (m, 7H, Harom+ Harom PPh3); 7.64 (d, 1H, J=7.9 
Hz, Harom); 7.57-7.48 (m, 11H, Harom + Harom PPh3); 6.41 (d, 1H, J=9.0 Hz, 
Harom). 
13C NMR: 149.2; 134.9 (d, J=10.6 Hz); 133.1; 131.2; 131.1; 128.7; 
128.2 (d, J=11.3 Hz); 127.9; 127.8; 127.5 (d, J=67 Hz); 127.4; 127.3; 
123.0; 122.7; 119.5. 31P NMR: 7.28 (JP-Pt=3829 Hz). 
195Pt NMR: -2909 
(JP-Pt=3829 Hz).  
 
O-Alkylation of bidentate oxime complexes  
 
[Pt(Cl)(PPh3){(κ
2-N,O)-[1(CHN(OCH2CH2Cl)-2(O)C10H6]}] (5) 
A Shlenk tube equipped with a magnetic stirrer was charged with a 1,2-
DCE solution of 4 (69.9 mg, 0.103 mmol in 10.0 ml), a 0.02 M solution of 
NaOH in water (10.0 mL) and a catalytic amount of tetrabutylammonium 
chloride (TBACl, 5 mol-%). The mixture was stirred at room temperature 
(25 °C) and the complete conversion of the precursor into a single 
product was checked spectroscopically (31P NMR, 24 h). After separating 
the two phases, the aqueous phase was extracted with portions of 1,2-
DCE (3 x 10 mL). The collected organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated up to 10 mL. The addition 
of heptane (20 mL) caused the precipitation of an orange solid, which 
was filtered, washed with heptane and dried under vacuum (40.5 mg, 
53 % isolated yield). C31H26Cl2NO2PPt∙H2O. Anal. Calc.: C 49.0, H 3.7, N 
1.8 %; Exp.: C 49.4, H 3.7, N 1.6 %. IR (ATR, 𝜈, cm-1): 2964; 2906; 1619; 
1602; 1541; 1507; 1481; 1429; 1407; 1335; 1259; 1084; 1015; 946; 863; 
796; 753; 710. 1H NMR: 9.42 (d, 1H, Harom); 7.89-7.79 (m, 8H, CHN + 
Harom); 7.63 (d, 2H, Harom); 7.55-7.46 (m, 13H, Harom); 7.24 (d, 1H, Harom); 
4.70 (t, 2H, OCH2); 3.83 (t, 2H, CH2Cl). 
13C NMR: 151.0; 135.0 (d, J=10.3 
Hz); 133.6; 131.0; 128.3 (d, J=80.5 Hz); 128.2 (d, J=10.9 Hz); 123.1; 
119.5; 76.4; 41.1. 31P NMR: 6.01 (JP-Pt=3807 Hz). 
195Pt NMR: -2849 (JP-
Pt=3807 Hz). 
 
 [PtCl(PPh3){(κ
2-N,O)-[1(CHN(OR)-2(O)C10H6]}] General procedure.  
A Shlenk tube equipped with a magnetic stirrer was charged with a 
solution of 4 in CHCl3 (about 0.15 mmol in 10.0 mL), RBr (RBr/Pt = 1.3 
molar ratio), a catalytic amount (5 mol-%) of TBACl and a 0.02 M solution 
of NaOH in water (10.0 mL). The mixture was stirred at room 
temperature (25 °C) and the complete conversion of the precursor was 
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checked spectroscopically (31P NMR, 2-5 h). After separating the two 
phases, the aqueous phase was extracted with portions of CHCl3 (3 x 10 
mL). The collected organic phases were dried over anhydrous Na2SO4, 
filtered and concentrated up to 10 mL. The addition of heptane (20 mL) 
caused the precipitation of an orange solid, which was filtered, washed 
with heptane and dried under vacuum. For each O-alkylated complex the 
alkyl bromide used, the isolated yield and the characterization are 
reported: 
 
[PtCl(PPh3){(κ
2-N,O)-[1(CHN(OBz)-2(O)C10H6]}] (6): BzBr, 50 % 
IR (𝜈, cm-1): 3055; 2963; 1619; 1599; 1533, 1434, 1332, 1300, 1189; 
1097; 1016; 949; 799, 743; 692. 1H NMR: 9.06 (d, 1H, J=8.4Hz, CHN); 
7.94-7.85 (m, 4H, HPPh3); 7.65 (m, 2H, HAr); 7.62-7.46 (m, 14H, HAr + 
HPPh3); 7.33-7.35 (m, 2H, HAr); 7.27-7.20 (m, 1H, HAr); 6.27 (d, 1H, 
HAr); 5.45 ppm (s, 2H, CH2Ph). 
13C NMR: 163.5, 151.4, 151.3, 135.4 
135.0, (d, J=11 Hz), 134.9, 133.3, 131.0, 129.9, 128.7, 128.5, 128.3, 
128.1 (d, J=10 Hz), 128.4 (d, J= 67 Hz), 127.6, 123.3, 122.9, 119.4, 
105.7, 79.7. 31P NMR: 6.47 (J=3783 Hz). 195Pt NMR: -2843 (J=3783 Hz).  
 
[PtCl(PPh3){(κ
2-N,O)-[1(CHN(O(CH2)4Br)-2(O)C10H6]}] (7): Br(CH2)4Br, 
71 %.  
C33H30BrClNO2PPt. Anal. Calc.: C 48.7, H 3.7, N 1.7 %; Exp.: C 48.7, H 
3.4, N 2.0 %. IR (𝜈, cm-1): 3055, 2943, 1615, 1596, 1533, 1504, 1435, 
1389, 1323, 1256, 1098, 1032, 961, 900, 868, 837, 746, 691. 1H NMR: 
9.27 (d, 1H, J = 8.6Hz, CHN); 7.88-7.83 (m, 7H, HAr); 7.63 (d, 1H, J = 7.7 
Hz, HAr); 7.59-7.44 (m, 11H, HAr); 7.28 (m, 1H, HAr); 6.26 (d, 1H, J = 7.7 
Hz, HAr); 4.45 (t, 2H, J=6.5 Hz, NOCH2); 3.53 (t, 2H, J = 6.5 Hz, CH2Br); 
2.15 (quint, 2H, J = 6.5 Hz, NOCH2CH2); 1.97 (quint, 2H, J = 6.5 Hz, 
CH2CH2Br). 
13C NMR: 163.6, 150.6, 150.5, 135.0 (d, J = 11 Hz), 134.8, 
133.2, 131.0, 128.8, 128.2 (d, J = 10 Hz), 127.6 (d, J = 64 Hz), 127.7, 
127.4, 123.0, 119.4, 106.0, 76.6, 33.9, 29.5, 26.6. 31P NMR: 6.45 
(J=3792 Hz). 195Pt NMR: -2843 (J=3792 Hz). 
 
Inhibition Growth Assay 
HeLa (human cervix adenocarcinoma cells) were grown in Nutrient 
Mixture F-12 [HAM] (Sigma Chemical Co.); A2780 (human ovarian 
carcinoma) and A2780cis (human ovarian carcinoma cisplatin-resistant) 
were grown in RPMI 1640 (Sigma Chemical Co.). 1.5g/L NaHCO3, 10 % 
heat-inactivated fetal calf serum (Invitrogen), 100 U/mL penicillin, 100 
μg/mL streptomycin, and 0.25 μg/mL amphotericin B (Sigma Chemical 
Co.) were added to the media. The cells were cultured at 37 °C in a moist 
atmosphere of 5 vol.-% carbon dioxide in air. HeLa cells (4 x 104), A2780 
(2.5 x 104) or A2780cis (2.5 x 104) were seeded into each well of a 24-
well cell culture plate. After incubation for 24 h, various concentrations of 
the test agents were added to the complete medium and incubated for a 
further 72 h. Stock solutions of new complexes were made in 
dimethylsulfoxide at 20 mM concentration and then diluted with complete 
medium in such a way that the final amount of solvent in each well did 
not exceed 0.5 vol.-%. Cisplatin was dissolved in 0.9 wt.-% NaCl. A 
Trypan blue assay was performed to determine cell viability. Cytotoxicity 
data were expressed as GI50 values, i.e., the concentration of the test 
agent inducing 50 % reduction in cell number compared with control 
cultures. 
 
X-Ray determinations 
Crystals of 4 were selected at room temperature (296 K), glued to glass 
fibers and analyzed with a Bruker Smart Breeze CCD diffractometer. 
Table 3 summarizes the lattice parameters and the space group. 
Intensity data were collected in the range of 2θ angles reported in Table 
3. After correction for Lorentz and polarization effects and for absorption, 
the structure solution was obtained using the direct methods contained in 
SHELXS program.[13] The hydrogen of oxime hydroxyl residue was found 
in the difference Fourier map, while the other hydrogen atoms were 
introduced in calculated positions. The final reliability factors of the 
refinement procedure, done using SHELXL program, [14] are listed in 
Table 3. Other control calculations were performed with the programs 
contained in the WINGX suite.[15]  
CCDC 1590522 for 4 contains the supplementary crystallographic data 
for this paper. These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre. 
 
Table 3. Crystal data and structure refinement for complex 4. 
 
Compound  4  
Empirical formula  C29H23ClNO2PPt  
Formula weight  678.99  
Temperature  296(2) K  
Wavelength  0.71073 Å  
Crystal system  Monoclinic  
Space group  C 2/c  
Unit cell dimensions a = 17.0248(7) Å α= 90°. 
 b = 9.7147(4) Å β= 101.871(2)°. 
    c = 30.9507(17) Å γ = 90°. 
Volume 5009.5(4) Å
3
  
Z 8  
Density (calculated) 1.801 Mg/m3  
Absorption coefficient 5.800 mm-1  
F(000) 2640  
Crystal size 0.250 x 0.204 x 0.030 mm
3
  
Theta range for data 
collection 
2.894 to 33.732°.  
Index ranges -26<=h<=26, -15<=k<=12, 
-46<=l<=37 
 
Reflections collected 33996  
Independent 
reflections 
9433 [R(int) = 0.0382]  
Completeness to theta 
= 25.242° 
99.8 %   
Refinement method Full-matrix least-squares 
on F2 
 
Data / restraints / 
parameters 
9433 / 0 / 316  
Goodness-of-fit on F2 0.961  
Final R indices 
[I>2sigma(I)] 
R1 = 0.0383, wR2 = 
0.0818 
 
R indices (all data) R1 = 0.0678, wR2 = 
0.0915 
 
Extinction coefficient n/a  
Largest diff. peak and 
hole 
1.628 and -0.879 e.Å
-3
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